Reasons to Hold Hinge Health Stock in Your Portfolio for Now

Zacks
Zacks에서 열기
Reasons to Hold Hinge Health Stock in Your Portfolio for Now

Hinge Health HNGE is well-positioned for sustained growth, driven by robust revenue growth, expanding opportunities in Migraine and gastrointestinal (GI) care and a scalable AI-powered MSK platform. The raised 2026 outlook, broader enterprise reach and growing sales pipeline further support the growth outlook. However, continued investments and Cylinder Health integration could weigh on margin expansion.

This Zacks Rank #3 (Hold) company’s shares have surged 148.2% in the year-to-date period compared with the 24.8% growth of the industry. The S&P 500 Composite has increased 12% during the said time frame.

The digital MSK care provider has a market capitalization of $9.19 billion. The company anticipates 30.7% growth for the next year and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 18.4%.

Zacks Investment Research
Image Source: Zacks Investment Research

Reasons Favoring HNGE’s Growth

Guidance Raise Reinforces Growth Outlook: Hinge Health’s second-quarter 2026 revenues jumped 53% year over year to $212.8 million, while LTM calculated billings rose 52% to $862 million, aided by stronger yields. Management raised 2026 revenue guidance to $856-$860 million and non-GAAP operating income guidance to $236-$244 million, implying a 28% margin at the midpoint. Third-quarter revenues are projected to be in the range of $223-$225 million, reflecting 45% growth at the midpoint and underscoring the improving contribution from enrolment, referrals and renewals.

Expanding Beyond Core MSK: Hinge Health is broadening its addressable market by applying its technology and distribution network to Migraine and GI care, with opportunities estimated to be $78 billion and $135 billion, respectively. Migraine adoption surged to more than 450 clients covering over 5 million eligible lives in the second quarter.

Hinge Health is also acquiring Cylinder Health for $105 million to accelerate its GI expansion, adding nearly 100 clients across 2 million lives. The deal is expected to contribute $7-$8 million in 2026 revenues, with a broader rollout planned for 2027, creating additional wallet-share opportunities across Hinge Health’s existing client base.

Strong Q2 Results: Hinge Health delivered a strong second-quarter 2026 performance, supported by higher member yield, robust billings growth, margin expansion and a growing client base. Product expansion remains a key growth driver, with Migraine Care reaching more than 450 clients and 5 million lives, while the $105 million Cylinder Health acquisition expands HNGE into GI care. Improving win rates, a healthy sales pipeline and broader health-plan distribution further strengthen its land-and-expand strategy and support sustained growth.

A Factor That May Offset HNGE’s Gains

Reinvestment and Integration Costs May Weigh on Operating Leverage: Hinge Health continues to invest in product expansion despite improving margins. In the second quarter of 2026, GAAP operating expenses totaled $143.5 million, including $81.4 million in sales and marketing expenses and $34.1 million in research and development. The planned $105 million acquisition of Cylinder Health is also expected to increase integration requirements, while the company plans to invest in its GI program ahead of a broader rollout in 2027.

Cylinder is expected to contribute only $7-$8 million in revenues in 2026 following the deal's closure. Although management raised its full-year non-GAAP operating margin guidance to 28% at the midpoint, higher-than-expected investments in GI, Migraine and other growth initiatives could moderate the pace of margin expansion.          

Estimate Trend

Hinge Health is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share (EPS) has remained stable at $2.38.

The Zacks Consensus Estimate for third-quarter 2026 revenues is pegged at $225.2 million, indicating a 46.1% improvement from the year-ago quarter’s reported number. The consensus mark for third-quarter EPS is pegged at 63 cents, implying an 85.3% improvement year over year.

Key Picks

Some better-ranked stocks from the broader medical space are OPKO Health OPK, Globus Medical GMED and Merit Medical Systems MMSI.

OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.

MMSI has an estimated long-term earnings growth rate of 10.4%. Merit Medical Systems’ earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Hinge Health Inc. (HNGE): Free Stock Analysis Report
 
Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report
 
OPKO Health, Inc. (OPK): Free Stock Analysis Report
 
Globus Medical, Inc. (GMED): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research